




The Diabetes Collaborative Registry Program Measures and Metrics

Measure ID	Measure Description	Developer	NQF #
DCR-1	Diabetes: Hemoglobin A1c Poor Control: Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period (12 months from date of encounter).	NCQA	0059
DCR-2	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy-Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%): Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have diabetes or a current or prior LVEF < 40% who were prescribed an ACE inhibitor or ARB therapy	ACCF	N/A
DCR-3	Diabetes: Medical Attention for Nephropathy: Percentage of patients 18-75 years of age with diabetes who had nephropathy screening test or evidence of nephropathy during the measurement period	NCQA	0062
DCR-4	Tobacco Use: Screening and Cessation Intervention: Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user	ACCF	N/A
DCR-5	Dietary Intake Counseling: Percentage of patients aged 18 and older with diabetes who were counseled to eat a healthy diet	AHA/ACCF	N/A
DCR-6	Physical Activity Counseling: Percentage of patients aged 18 and older with diabetes who were counseled to engage in regular physical activity	AHA/ACCF	N/A
DCR-7	Peripheral Artery Disease (PAD): Treatment of Blood Cholesterol to Reduce Atherosclerotic Risk: Percentage of patients 18-75 years of age with PAD who were offered moderate-to-high intensity statin	AHA/ACCF	N/A
DCR-8	Diabetes Eye Exam: Percentage of patients aged 18 and older with diabetes who received an eye exam	NCQA	0055
DCR-9	Diabetes Foot Exam: Percentage of patients aged 18 and older with diabetes who received a foot exam	NCQA	0056
DCR-10	Diabetes Advance Care Plan: Percentage of patients aged 65 years and older who have a diagnosis of diabetes and who have an advance care plan or surrogate decision marker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan	ACC	N/A

Measure ID	Measure Description	Developer	NQF #
DCR-11	Antiplatelet Therapy: Percentage of patients aged 18 and older who received antiplatelet therapy to reduce the risk of myocardial infarction, stroke, or vascular death in patients with a history of symptomatic PAD	ACCF/AHA/ ACR/SCAI/ SIR/SVM/ SVN/SVS	N/A
DCR-13	Coronary Artery Disease (CAD): Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Percentage of patients ages 18-75 with CAD who were offered moderate-to-high intensity statin	ACC/AHA/ AMA-PCPI	N/A
DCR-15	Hypertension: Blood Pressure Treatment and Control for High Risk Patients: Proportion of adults, ≥ 18 years of age, with both hypertension and diabetes who were prescribed antihypertensive medication or who had adequately controlled blood pressure	ACCF	N/A

Unless indicated, the Diabetes Collaborative Registry® measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer programs or other forms of accountability. For additional information related to the metrics, refer to this website: <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents>

Diabetes Collaborative Registry participants include clinicians in primary care, endocrinology, and cardiology outpatient settings. Eligible providers must be able to report 7 of the metrics listed above to participate in the Diabetes Collaborative Registry.



Veradigm® is an Allscripts company.

©2021 Veradigm® Allscripts Healthcare LLC, and/or its affiliates. All rights reserved. Cited marks are the property of Allscripts Healthcare, LLC and or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.